Company

Eupraxia Pharmaceuticals Inc.

Headquarters: Victoria, BC, Canada

Employees: 12

CEO: Dr. James A. Helliwell FRCPC, M.D.

TSX: EPRX +3.85%

Market Cap

C$124.7 Million

CAD as of July 1, 2024

US$90.8 Million

Market Cap History

Eupraxia Pharmaceuticals Inc. market capitalization over time

Evolution of Eupraxia Pharmaceuticals Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Eupraxia Pharmaceuticals Inc.

Detailed Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Eupraxia Pharmaceuticals Inc. has the following listings and related stock indices.


Stock: TSX: EPRX wb_incandescent

Details

Headquarters:

2067 Cadboro Bay Road

Suite 201

Victoria, BC V8R 5G4

Canada

Phone: 250-590-3968

Fax: 250-590-2588